APRiCOT-L: Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-small Cell Lung Cancer

NCT00652340 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Non Small Cell Lung Cancer

Interventions

DRUG: apricoxib/erlotinib
DRUG: erlotinib/placebo

Sponsor

Tragara Pharmaceuticals, Inc.